| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 18.539 | 17.410 | 14.999 | 15.204 | 14.608 | 10.012 | 5.660 | 6.309 | 5.321 | 6.501 |
| Total Income - EUR | 18.571 | 17.410 | 15.008 | 15.204 | 14.608 | 10.012 | 5.660 | 6.309 | 5.321 | 6.501 |
| Total Expenses - EUR | 12.030 | 7.998 | 7.452 | 10.372 | 9.392 | 10.498 | 6.577 | 8.397 | 4.927 | 2.893 |
| Gross Profit/Loss - EUR | 6.540 | 9.412 | 7.556 | 4.831 | 5.216 | -486 | -917 | -2.087 | 394 | 3.608 |
| Net Profit/Loss - EUR | 5.983 | 8.890 | 7.102 | 4.375 | 4.778 | -787 | -1.087 | -2.277 | 331 | 3.031 |
| Employees | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Roprax Medical S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 3.411 | 2.237 | 1.080 | 376 | 0 | 1.033 | 606 | 203 | 0 | 474 |
| Current Assets | 62.733 | 71.705 | 28.509 | 14.264 | 15.433 | 13.418 | 13.433 | 10.267 | 11.956 | 5.610 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 4.691 | 4.765 | 5.147 | 3.239 | 5.582 | 2.803 | 3.516 | 2.724 | 2.736 | 0 |
| Cash | 58.041 | 66.940 | 23.362 | 11.025 | 9.851 | 10.615 | 9.918 | 7.543 | 9.220 | 5.610 |
| Shareholders Funds | 64.916 | 73.143 | 6.288 | 10.548 | 15.121 | 14.048 | 12.650 | 10.412 | 10.711 | 5.731 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 1.227 | 799 | 23.302 | 4.093 | 312 | 404 | 1.390 | 58 | 1.244 | 352 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8621
|
|||||||||
Comments - Roprax Medical S.r.l.